Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Objective: To assess the safety and tolerability and to explore the preliminary efficacy of intermittent intraputamenal monthly infusions of CDNF in subjects with advanced idiopathic…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
Objective: To test if intermittent intraputamenal monthly infusions of CDNF have an effect on striatal dopamine transporter (DAT) binding, as measured by PET, in subjects…Cardiovascular Fitness, Plasma Biomarkers and Dopaminergic Denervation in Parkinson’s Disease
Objective: To examine the relationship between cardiovascular (CV) fitness, plasma biomarkers associated with PD progression and/or exercise and dopaminergic denervation, measured by I-123-Ioflupane single photon…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease
Objective: To consolidate current opinion on trial methodology of disease modifying therapies (DMTs) for Parkinson’s disease (PD) and establish consensus on a core protocol for…Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease
Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)
Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…New tool to localize seizure onset zone from sEEG signal-connectivity epileptogenicity index
Objective: The main diagnostic challenge of drug resistant epilepsies is to find epileptogenic zone, which will be enough to remove to reach seizure freedom. These…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 16
- Next Page »